Dr. Reddy’s Laboratories has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by the U.S. Food & Drug Administration (USFDA). Dr. Reddys Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.
The Evista brand and generic had U.S. sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health. Evista is a registered trademark of Eli Lilly and company.
Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
